Search

Additional file 6: Table 1. Frequently reported TEAEs (���10% of patients in ���1 treatment arm) in parts 2 and 3 of the study, stratified by dialysis modality.

Additional file 1: Figure 1. Proportion of patients who did not have serum phosphorus data available or who did not satisfy other eligibility criteriaa after 8 weeks of CC followed by 8 weeks of LC (A) and after at least 8 weeks of LC (B); these patients were thus excluded from the efficacy analyses (per-protocol sets 1 and 2).

Additional file 4: Table 1. TEAEs considered related to study drug, experienced by ���1 patient in ���1 treatment arm.

Additional file 5: Table 1. Change from baseline in biochemical bone markers for patients in part 2 of the studya.

Additional file 3: Table 1. Baseline demographics and characteristics of CC- and LC-treated patients, stratified by dialysis mode.

Additional file 2: Table 1. List of center that participated in this study.